Abstract: A method for preparing polyanhydroglucuronic acid and/or salts thereof is described. A polyanhydroglucuronic acid-containing material obtained by oxidation is subjected to partial or complete hydrolysis to form a homogeneous system, subsequent ion exchange in the homogeneous system; and supplemental oxidation in the presence of any one or more of organic and inorganic peroxides.

Abstract: A method for preparing polyanhydroglucuronic acid and/or salts thereof is described. A polyanhydroglucuronic acid-containing material obtained by oxidation is subjected to partial or complete hydrolysis to form a homogeneous system, subsequent ion exchange in the homogeneous system; and supplemental oxidation in the presence of any one or more of organic and inorganic peroxides.

Abstract: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6 and 3,6 hemiacetals, 2,4-hemialdals and C2 and C3 aldehydes. The molecular mass of the polymeric chain is from 1×103 to 3×105 Daltons. The microdispersed products are prepared by subjecting a polyanhydroglucuronic acid-containing material to partial or complete hydrolysis and neutralization in an oxidative environment.

Abstract: A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.

Abstract: A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.

Abstract: A slow release formulation includes a biocompatible anionic polysaccharide material containing glucuronic acid in the polymer chain.

Abstract: An antilipemic composition, particularly to achieve a lowering of cholesterol levels comprises a biocompatible anionic polysaccharide material containing non-sulphated glucuronic acid.

Abstract: A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.

Abstract: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6 and 3,6 hemiacetals, 2,4-hemialdals and C2 and C3 aldehydes. The molecular mass of the polymeric chain is from 1×103 to 3×105 Daltons. The microdispersed products are prepared by subjecting a polyanhydroglucuronic acid-containing material to partial or complete hydrolysis and neutralisation in an oxidative environment.

Abstract: A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.

Abstract: Wounds involving minor lesions such as cuts, excoriations, burns, scalds and various kinds of open efflorescence require rapid covering to arrest bleeding, to disinfect the wound area and to suppress secondary microbial contamination. The present invention is a hemostatically active aerosol composition comprised of microdispersed polyanhydroglucuronic acid and salts thereof and from 0.75 to 0.995 parts by weight of a dispergating/propellant system. The system includes compounds which are nonpolar or of low polarity with a surface tension of less than 30 mN/M and a permitivity of 10 kilohertz of less than 10 and at least one compound selected from the group consisting of a fluorinated or perfluorinated alkane, a C3 to C8 cycloalkane and a fluorinated or perfluorinated aliphatic ether.

Abstract: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 per cent by weight of carboxyl groups, at least 80 per cent by weight of these groups being of the uronic type, at most 5 per cent by weight of carbonyl groups including intra- and inter-molecular 2,6 and 3,6 hemiacetals, 2,4-hemialdals and C2-C3 aldehydes. The molecular mass of the polymeric chain is from 1×103 to 3×105 Daltons. The microdispersed products are prepared by subjecting a polyanhydroglucuronic acid-containing material to partial or complete hydrolysis and neutralisation in an oxidative environment.

Abstract: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups including intra- and inter-molecular 2,6 and 3,6 hemiacetals, 2,4-hemialdals and C2 and C3 aldehydes. The molecular mass of the polymeric chain is from 1×103 to 3×105 Daltons. The microdispersed products are prepared by subjecting a polyanhydroglucuronic acid-containing material to partial or complete hydrolysis and neutralisation in an oxidative environment.

Abstract: A pharmaceutical composition for the prophylaxis or treatment of peptic ulcers includes a biocompatible anionic polysaccharide material containing glucuronic acid.

Abstract: Stable microdispersed polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 per cent by weight of carboxyl groups, at least 80 per cent by weight of these groups being of the uronic type, at most 5 per cent by weight of carbonyl groups including intra- and inter-molecular 2,6 and 3,6 hemiacetals, 2,4-hemialdals and C2-C3 aldehydes. The molecular mass of the polymeric chain is from 1×103 to 105 Daltons. The microdispersed products are prepared by subjecting a polyanhydroglucuronic acid-containing material to partial or complete hydrolysis and neutralisation in an oxidative environment.

Abstract: A slow release formulation includes a biocompatible anionic polysaccharide material containing glucuronic acid in the polymer chain.

Abstract: An antilipemic composition, particularly to achieve a lowering of cholesterol levels comprises a biocompatible anionic polysaccharide material containing non-sulphated glucuronic acid.